Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?
Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.
Overview
Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), disposed of 363,200 shares of common stock on July 15, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($4.09); post-transaction value based on July 15, 2026, market close ($4.09).
Details
MannKind Corporation is a biopharmaceutical firm with a market capitalization of $1.2 billion, employing 592 professionals focused on developing and commercializing respiratory-delivered treatments. The company has achieved TTM revenue of $360.8 million while managing a net loss of $23.9 million, reflecting the capital-intensive nature of biopharmaceutical development and commercialization. MannKind's competitive positioning centers on its proprietary inhalation technology platform and specialized focus on respiratory-delivered therapeutics for endocrine and pulmonary conditions.
Source
Originally published at www.fool.com.